Reuters  Jul 4  Comment 
Britain's Supreme Court dismissed on Wednesday an appeal by Goldman Sachs for compensation from Portugal's Novo Banco over a $835 million loan to Novo Banco's bankrupt predecessor, Banco Espirito Santo (BES), which was carved up by the state in 2014.
Financial Times  Jul 3  Comment 
Winterbrook Capital pursues Portuguese lender over ‘defaulted’ bonds
Financial Times  Jun 29  Comment 
European bank debt fine print offers opportunities for savvy hedge funds
FiercePharma  Jun 28  Comment 
Just eight days after posting a trial win over Merck diabetes stalwart Januvia, Novo Nordisk candidate semaglutide is back with another.
FierceBiotech  Jun 28  Comment 
Novo Holdings has invested CHF 20 million ($20 million) in NBE Therapeutics, doubling the size of the startup’s series B round. NBE will use the money to start testing anti-ROR1 antibody-drug conjugate (ADC) NBE-002 in solid tumor patients.
Financial Times  Jun 28  Comment 
Winterbrook Capital outlines reasons for questioning status of bank’s senior bonds
FiercePharma  Jun 25  Comment 
Patients on Eli Lilly's Trulicity were more likely to continue therapy and be adherent than those on Novo's Victoza and AstraZeneca's Bydureon, according to a study examining U.S. claims data.
FiercePharma  Jun 21  Comment 
Once it wins approval, Novo Nordisk’s highly anticipated oral diabetes drug semaglutide will go up against some stiff competition. But the drugmaker just showed that its up-and-comer can take the heat.

You may also be interested in articles related to Novo Nordisk A/S (NVO):


Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki